Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 15 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Celecoxib Capsules in various dosages. Celecoxib is a nonsteroidal anti-inflammatory drug used to treat pain and inflammation from conditions like arthritis and menstrual pain. The capsules will be produced at Zydus Lifesciences' facility in Ahmedabad, and the product had significant annual sales in the United States. This filing serves to inform investors and the stock exchange about the approval and its implications for the company.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 15, 2025, titled "Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases